<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Relaxin-2 Does Not Ameliorate Nephropathy in an Experimental Model of Type-1 Diabetes</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2015-03-05">March 05, 2015</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Thomas</forename><forename type="middle">Bernd</forename><surname>Dschietzig</surname></persName>
							<email>thomas.dschietzig@t-online.de</email>
							<affiliation key="aff0">
								<orgName type="institution">Immundiagnostik AG</orgName>
								<address>
									<settlement>Bensheim</settlement>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Cardiology and Angiology</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Katharina</forename><surname>Krause-Relle</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Center for Cardiovascular Research</orgName>
								<orgName type="institution">Charité Berlin</orgName>
								<address>
									<addrLine>Campus Mitte</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Institute for Nutritional Science</orgName>
								<orgName type="institution">University of Potsdam</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Maud</forename><surname>Hennequin</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Institute for Veterinary Physiology</orgName>
								<orgName type="institution">Free University of Berlin</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Karoline</forename><surname>Von Websky</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Center for Cardiovascular Research</orgName>
								<orgName type="institution">Charité Berlin</orgName>
								<address>
									<addrLine>Campus Mitte</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Institute for Nutritional Science</orgName>
								<orgName type="institution">University of Potsdam</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jan</forename><surname>Rahnenführer</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Center for Cardiovascular Research</orgName>
								<orgName type="institution">Charité Berlin</orgName>
								<address>
									<addrLine>Campus Mitte</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Institute for Nutritional Science</orgName>
								<orgName type="institution">University of Potsdam</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jana</forename><surname>Ruppert</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution">Immundiagnostik AG</orgName>
								<address>
									<settlement>Bensheim</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hans</forename><forename type="middle">Jürgen</forename><surname>Grön</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution">Immundiagnostik AG</orgName>
								<address>
									<settlement>Bensheim</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Franz</forename><forename type="middle">Paul</forename><surname>Armbruster</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution">Immundiagnostik AG</orgName>
								<address>
									<settlement>Bensheim</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ross</forename><forename type="middle">A D</forename><surname>Bathgate</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Biochemistry and Molecular Biology</orgName>
								<orgName type="institution" key="instit1">Florey Institute of Neuroscience and Mental Health</orgName>
								<orgName type="institution" key="instit2">University of Melbourne</orgName>
								<address>
									<settlement>Melbourne</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Joerg</forename><forename type="middle">R</forename><surname>Aschenbach</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Institute for Veterinary Physiology</orgName>
								<orgName type="institution">Free University of Berlin</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Wolf-Georg</forename><surname>Forssmann</surname></persName>
							<affiliation key="aff6">
								<orgName type="institution">PHARIS Biotec</orgName>
								<address>
									<settlement>Hannover</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Berthold</forename><surname>Hocher</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Center for Cardiovascular Research</orgName>
								<orgName type="institution">Charité Berlin</orgName>
								<address>
									<addrLine>Campus Mitte</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Institute for Nutritional Science</orgName>
								<orgName type="institution">University of Potsdam</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>Prof. Dr</roleName><forename type="first">Med</forename><surname>Thomas</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Bernd</forename><surname>Dschietzig</surname></persName>
						</author>
						<author>
							<affiliation key="aff7">
								<orgName type="institution">Immundiagnostik AG</orgName>
								<address>
									<addrLine>Stubenwaldallee 8a</addrLine>
									<postCode>64625</postCode>
									<settlement>Bensheim</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Relaxin-2 Does Not Ameliorate Nephropathy in an Experimental Model of Type-1 Diabetes</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2015-03-05">March 05, 2015</date>
						</imprint>
					</monogr>
					<idno type="MD5">4F2292DB42DB69D7C7692935FD28D29F</idno>
					<idno type="DOI">10.1159/000368484</idno>
					<note type="submission">Accepted: February 03, 2015</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:44+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Diabetic nephropathy</term>
					<term>Diabetic cardiomyopathy</term>
					<term>Fibrosis</term>
					<term>Inflammation</term>
					<term>Relaxin Relaxin and Diabetic Nephropathy</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license),</s><s>applicable to the online version of the article only.</s><s>Distribution permitted for non-commercial purposes only.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>In spite of the enormously rising prevalence of diabetes mellitus in industrialized countries <ref type="bibr" target="#b0">[1]</ref>, clinical medicine as well as health economy are equally challenged to manage the different facets of diabetic end-organ damage.</s><s>Among these deleterious ramifications of diabetes, diabetic nephropathy (DN) plays the major role and represents the leading cause worldwide of end-stage renal disease <ref type="bibr" target="#b1">[2]</ref>.</s><s>Likewise, diabetic cardiomyopathy (DC), defined as diastolic and/or systolic dysfunction in the absence of hypertension and coronary artery disease <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b3">4]</ref>, is another serious complication contributing to the overall diabetic risk burden.</s><s>Prevention and treatment of DN are based on the control of hyperglycemia, the treatment of concomitant classic risk factors, and the therapeutic inhibition of the renin-angiotensinaldosterone system (RAAS) <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b5">6]</ref>.</s><s>However, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are frequently ineffective in preventing DN despite an optimal control of hyperglycemia and risk factors.</s><s>For DC, no specific pharmacological therapy at all has been identified hitherto.</s><s>This illustrates the pathophysiological involvement of pathways distinct from RAAS and the urgent need for novel therapeutic approaches.</s></p><p><s>The insulin-related endogenous peptide hormone relaxin-2 (Rlx) may pose such a novel candidate drug.</s><s>Signaling via its cognate G protein-coupled receptor, RXFP1 <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b7">8]</ref>, and the glucocorticoid receptor <ref type="bibr" target="#b8">[9]</ref> Rlx has been demonstrated to exert the following effects that may address major hallmarks of DN and DC: Above all, Rlx is one of the most powerful anti-fibrotic agents in many different models of heart, lung, kidney, and liver fibrosis <ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref>.</s><s>It has recently been shown to be superior to enalapril in experimental cardiac fibrosis <ref type="bibr" target="#b15">[16]</ref>.</s><s>Rlx is a renal vasodilator stimulating the NO-cGMP axis <ref type="bibr" target="#b16">[17,</ref><ref type="bibr" target="#b17">18]</ref>.</s><s>It protects against endothelial dysfunction <ref type="bibr" target="#b18">[19]</ref> and early vascular inflammation <ref type="bibr" target="#b19">[20]</ref>, and counter-acts the vasoconstrictory as well as pro-inflammatory actions of endothelin-1 <ref type="bibr" target="#b20">[21]</ref>.</s><s>Moreover, Rlx inhibits several markers of oxidative stress in different animal models <ref type="bibr" target="#b13">[14,</ref><ref type="bibr" target="#b18">19,</ref><ref type="bibr" target="#b21">22]</ref>.</s><s>However, in the type-1 diabetic mRen-2 rat, Rlx affected end-organ damage differentially: DC was markedly improved as reflected by less interstitial myocardial fibrosis and better diastolic function <ref type="bibr" target="#b22">[23]</ref>.</s><s>In contrast, DN as assessed by urinary albumin loss, interstitial collagen, and glomerulosclerosis was not modified at all <ref type="bibr" target="#b23">[24]</ref>.</s><s>In this work, we sought to investigate whether this striking dissociation represents a species-related phenomenon.</s><s>Accordingly, we investigated the effects of two different doses of Rlx in an established mouse model of type-1 diabetes which closely mimics the pathophysiology of human DN <ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref> and DC <ref type="bibr" target="#b27">[28]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study design</head><p><s>This study was carried out in strict accordance with the recommendations in the ''Guide for the Care and Use of Laboratory Animals of the National Institutes of Health''.</s><s>The protocol was approved by the local animal welfare committee of the German State of Berlin (project no.</s><s>G0209/10).</s><s>All surgical procedures were performed under inhalation anesthesia with isoflurane, and all efforts were made to minimize suffering.</s></p><p><s>Eight-week old male eNOS (NOS3) knock out C57BL/6J mice (C57BL/6J-Nos3tm1Unc; n= 74) were obtained from The Jackson Laboratory (Bar Harbor, ME, USA).</s><s>The eNOS -/genotype is known to greatly aggravate albuminuria in diabetic models <ref type="bibr" target="#b25">[26,</ref><ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b29">30]</ref>; and it was the main focus of our study to evaluate the effect of Rlx on this important clinical end-point of DN.</s><s>The gain of albuminuria is particularly high in eNOS-KO animals treated with the high-dose STZ protocol <ref type="bibr" target="#b24">[25]</ref>, which for us outweighed the greater propensity for non-specific cytotoxic effects related to the high-dose regimen.</s><s>At last, eNOS-KO on a BLKS background are more susceptible to DN than B6 animals <ref type="bibr" target="#b24">[25,</ref><ref type="bibr" target="#b29">30]</ref>, but here our choice was merely guided by the issue of commercial availability at study beginning.</s></p><p><s>In accordance with local institutional guidelines for the care and use of laboratory animals, mice were housed under standardized conditions (12 h light/dark cycle, temperature of 23 °C, humidity of 50-60%) and kept in solitary cages with commercial standard diet (Ssniff Spezialdiäten GmbH, Soest, Germany) and water ad libitum.</s><s>Before induction of diabetes by streptozotocin (STZ), baseline blood pressure was measured using the non-invasive tail-cuff method and metabolic cages were performed.</s><s>Then mice intraperitoneally received STZ (100 mg/kg body weight) on 2 consecutive days.</s><s>Four weeks after STZ treatment, hyperglycemia &gt;250 mg/dl was confirmed.</s><s>The diabetic mice were then randomly divided into the following groups (n = 20 each): vehicle, low-dose Rlx (32 µg/kg/d), and high-dose Rlx (320 µg/kg/d).</s><s>Another 14 mice served as non-diabetic controls and received vehicle after they had been administered citrate buffer instead of STZ in equal volume.</s><s>The high dose Rlx was chosen based on previous reports in mice and rats <ref type="bibr" target="#b30">[31,</ref><ref type="bibr" target="#b31">32]</ref> (see also Discussion).</s><s>The lower dose was based on the mere rationale that many long-term effects of peptides can also be observed at sub-maximum levels.</s></p><p><s>Treatment was conducted for 12 weeks which necessitated the implantation of Alzet-2006 osmotic mini-pumps (Charles River) at beginning and at week 6 of Rlx/vehicle administration.</s><s>The pump reservoirs (250 µl) were loaded with vehicle alone, 0.105 mg, and 1.05 mg Rlx for the control, low-dose, and highdose groups, respectively.</s><s>At treatment weeks 5 and 10, baseline measurement of blood pressure and metabolic cages were performed; blood glucose levels were determined immediately before the different Alzet implantations.</s><s>Final procedures in treatment week 12 (i.</s><s>e., week 16 after STZ) included collection of urine and blood samples as well as animal sacrifice including determination of organ wet weights and harvest for histology.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Histology</head><p><s>Renal and myocardial morphology (interstitial fibrosis, perivascular fibrosis, glomerulosclerosis, myocyte diameter, and media-lumen ratio of blood vessels) was measured as described previously <ref type="bibr" target="#b32">[33]</ref>.</s><s>In brief, glomerular matrix expansion was evaluated on periodic acid-Schiff (PAS)-stained slides by rating the percentage of the PAS-positive areas within the glomerulus using a subjective, semi-quantitative score system (grade I-IV) by two investigators who were blinded to the study groups of the animals.</s><s>The severity of interstitial fibrosis was evaluated after Sirius Red-staining using computer-aided devices.</s><s>Thirty microscopic pictures per kidney/heart section were transferred to a PowerMAC via Hitachi CCD camera.</s><s>After manually setting a threshold using a randomly chosen subset of the pictures, we measured the relationship of Sirius Red-stained area (connective tissue) to total area of the picture using ImageJ, an image-processing software (shareware from the National Institutes of Health).</s><s>Accordingly, microscopic pictures of kidney/heart sections after Elastica-van Gieson staining that showed arterial blood vessels were generated.</s><s>We measured the area contents of the media and the lumen of intra-renal arteries using ImageJ; thereafter, media/lumen ratio was calculated to serve as marker for arterial wall thickening.</s><s>Likewise, we determined myocyte diameters in myocardium.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Western Blotting</head><p><s>Proteins of murine kidney were extracted as previously described <ref type="bibr" target="#b33">[34]</ref>, additionally supplemented with inhibitor of phosphatases (PhosStop, Roche diagnostics, Indianapolis, IN).</s><s>Proteins were electrophoretically separated and transferred to a nitrocellulose membrane using semi-dry equipment.</s><s>The membranes were blocked and incubated with primary antibodies against TGF-β (sc-146, Santa Cruz Biotechnology, Santa Cruz, CA) or phosphorylated Smad 2/3 (sc-11769-R, Santa Cruz).</s><s>Immunostaining with antibodies against total Smad 2/3 (sc-6202, Santa Cruz) or actin (A5060, Sigma-Aldrich) was used as internal control.</s><s>Then membranes were incubated with host-specific HRP-coupled secondary antibodies (sc-2054 or sc-2056, Santa Cruz).</s><s>Immunoreactive bands were visualized with chemoluminescence detection as described before <ref type="bibr" target="#b34">[35]</ref> and exposure to an autoradiography film (Amersham Hyperfilm ECL (GE healthcare, Chalfont St. Giles, UK)).</s><s>Photos were scanned and the protein bands were quantified using AlphaEaseFC software (Alpha Innotech, San Leandro, CA).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Biochemical parameters</head><p><s>Urinary albumin was measured using an enzyme-linked immuno-sorbent assay (ELISA) according to the manufacturer's instructions (Immundiagnostik, Bensheim, Germany).</s><s>Urinary and plasma creatinine were measured spectrophotometrically based on the Jaffé reaction of creatinine with alkaline picrate (Limbach Laboratory, Heidelberg, Germany).</s><s>Urinary malonyldialdehyde (MDA) was determined by HPLC (Immundiagnostik AG).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Synthetic Rlx: biological effects and plasma levels</head><p><s>Synthetic human relaxin-2 was synthesized by PHARIS Biotec (Hannover, Germany).</s><s>Its biological effects were verified as follows:</s></p><p><s>Ligand binding assay.</s><s>We performed competition binding experiments utilizing HEK-293T cells stably transfected with RXFP1 and europium-labeled human relaxin-2 according to Shabanpoor et al. <ref type="bibr" target="#b35">[36]</ref>.</s><s>Briefly, cells were plated out in 96-well Isoplates with white walls and clear bottoms precoated with poly-L-lysine.</s><s>Competition binding experiments were carried out using europium-labeled Rlx in the presence of increasing concentrations of synthetic Rlx or of the reference substance, recombinant human relaxin-2 (Corthera, San Carlos, USA).</s><s>Non-specific binding was determined with an excess (500 nM) of unlabeled Rlx.</s><s>Each concentration point was performed in triplicate and peptides were tested in at least three independent assays to confirm activity.</s><s>Curves were fitted using a one site-binding model in GraphPad Prism 4.0 (GraphPad Software, San Diego, CA, USA).</s><s>The inhibition constants (K i ) as a measure of peptide activity were determined from the IC 50 values using the Cheng-Prusoff equation, with pKi being the negative decadic logarithm of the inhibition constant K i .</s></p><p><s>Functional cAMP assay: cAMP reporter gene assays were carried out as described by Yan et al. <ref type="bibr" target="#b36">[37]</ref>.</s><s>Briefly, HEK-293T cells stably expressing RXFP1 and a pCRE-β-galactosidase reporter plasmid were utilized to determine the ability of synthetic Rlx to activate RXFP1-related signaling.</s><s>Stimulation of RXFP1 results in the activation of adenylate cyclase and consequently in an increase in cAMP and subsequent activation of the pCRE reporter.</s><s>Cells were incubated for 6 hours with increasing concentrations of synthetic Rlx or of the reference substance, recombinant human relaxin-2 (Corthera, San Carlos, USA).</s><s>Each concentration point was performed in triplicate and peptides were tested in at least three independent experiments.</s><s>Data were analyzed with GraphPad Prism 4.0 (GraphPad Software, San Diego, CA, USA), and a nonlinear regression sigmoidal dose-response (variable slope) model was used to plot curves and calculate pEC 50 values, with pEC 50 being the negative decadic logarithm of the half-maximum concentration.</s></p><p><s>Upon sacrifice of the animals, blood was collected for the determination of therapeutic Rlx levels by a commercially available ELISA for human Rlx (Immundiagnostik, Bensheim, Germany).</s><s>Plasma was diluted 1:44 in assay buffer, and the ELISA was used according to the manufacturer's instructions.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analyses</head><p><s>All values are given as means ± standard error of the mean (SEM).</s><s>Statistical analyses were performed with SPSS 18.0 for Windows (SPSS Inc., Chicago, IL, USA).</s><s>For comparisons between the four groups of interest, the Kruskal-Wallis ANOVA on ranks was used.</s><s>If global significance was indicated pair-wise comparisons were made with the Mann-Whitney U test and Bonferroni-Holm adjustment of P. For comparisons within groups over time, the Friedman ANOVA on ranks was used followed by Wilcoxon tests with P adjustment as described above.</s><s>Differences were considered significant if P &lt; 0.05 and highly significant if P &lt; 0.01.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Mortality and blood pressure</head><p><s>In the non-diabetic control group, mortality was 7 % (1 animal of 14).</s><s>Mortality in the 3 diabetes groups was clearly higher, i. e., 40 % in the vehicle group (8 of 20), 55 % in the lowdose Rlx group (11 of 20), and 50 % in the high-dose Rlx group (10 of 20).</s><s>The prematurely deceased animals were not analysed.</s></p><p><s>At weeks 5 and 10, systolic blood pressure was decreased in all diabetic animals as compared to non-diabetic controls, with no further effect of Rlx thereon (data not shown).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Blood glucose and body weight baseline vs final</head><p><s>As summarized in Table <ref type="table" target="#tab_0">1</ref>, diabetic animals did not gain weight significantly and showed severely elevated glucose levels at final examination.</s><s>These characteristics were not affected by Rlx at either dose.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Kidney function and urine analysis</head><p><s>Plasma creatinine levels in non-diabetic controls were 43 ± 5.2 and 59 ± 5.2 µmol/l at baseline and final examination, respectively.</s><s>In the different diabetic groups, these levels showed a trend towards lower values which did not reach significance (data not shown).</s></p><p><s>In diabetic controls, albuminuria increased markedly over 16 weeks as compared with non-diabetic controls, and neither dose of Rlx changed these values (Fig. <ref type="figure" target="#fig_0">1A</ref>).</s><s>Regarding diabetes-related oxidative stress, we detected a massive increase in creatinine-normalized urinary MDA levels in the diabetic controls which was not attenuated by the different Rlx regimes (Fig. <ref type="figure" target="#fig_0">1B</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Organ weight and histology (Table 2)</head><p><s>The STZ-induced diabetes elevated the relative weights of the kidneys and liver, but did not change relative heart weight.</s><s>Rlx treatment had no effect on kidney and liver weight.</s></p><p><s>With regard to kidney histology, the diabetes-induced increases in glomerulosclerosis score (Fig. <ref type="figure" target="#fig_1">2</ref>) and glomerular size were mitigated by neither dose of Rlx.</s><s>Perivascular and interstitial fibrosis as well as media-to-lumen ratio of intra-renal arteries were not altered in diabetic as compared to non-diabetic animals.</s></p><p><s>Myocardial perivascular and interstitial fibrosis was not changed during the course of disease in this model.</s><s>However, myocyte diameters in all diabetic groups decreased significantly in comparison with non-diabetic controls, with neither dose of Rlx showing an effect hereon.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>TGF-β involvement</head><p><s>In spite of the non-effectiveness of Rlx to ameliorate renal functional (albuminuria and MDA) and the related histological alterations (glomerulosclerosis and related inflammation) we sought to determine whether the key target of Rlx's anti-fibrotic action, TGF-β, contributed to the observed pathology in our model.</s><s>Fig. <ref type="figure" target="#fig_2">3</ref> shows that renal TGF levels were slightly, but significantly down-regulated in diabetic controls as compared with non-diabetic animals.</s><s>Similarly, the phosphorylation of the TGF-dependent transcription factors Smad-2 and -3 showed a downward trend in the diabetic groups which reached significance after high-dose Rlx treatment.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Assessment of Rlx activity</head><p><s>Competition binding experiments utilizing HEK-293T cells yielded a pK i of 9.3 ± 0.15 and 9.0 ± 0.05 for synthetic Rlx and recombinant Rlx, respectively (data not shown).</s><s>cAMP reporter gene assays showed a pEC 50 of 10.4 ± 0.05 for synthetic and 10.2 ± 0.04 for recombinant Rlx (not shown).</s><s>The final therapeutic plasma levels of Rlx were 1.27 ± 0.24 and 6.43 ± 1.0 ng/ml in the low-dose and high-dose groups, respectively.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Table 2. Organ weights (normalized to body weight [BW]</head><p><s>) and histological parameters (data are mean ± SEM).</s><s>#, P &lt; 0.05 vs non-diabetic controls; ##, P &lt; 0.01 vs non-diabetic controls The eNOS-knockout/STZ model used here was introduced by Nakagawa et al. <ref type="bibr" target="#b26">[27]</ref> and its principal features were confirmed by Kanetsuna et al. shortly thereafter <ref type="bibr" target="#b25">[26]</ref>.</s><s>The observed high mortality in our study corresponds well with that reported in Nakagawa's work in which it was ~50 % at week 20 <ref type="bibr" target="#b26">[27]</ref>.</s><s>Accordingly, this model is characterized by an inherent survival bias.</s><s>In line with the early reports on this model <ref type="bibr" target="#b25">[26,</ref><ref type="bibr" target="#b26">27]</ref>, we observed an early and moderate type of DN with plasma creatinine still in the normal range and increased relative kidney weight.</s><s>The prevailing histological findings were glomerulosclerosis as well as glomerular enlargement (Table <ref type="table">2</ref>).</s><s>The pathology did not involve interstitial fibrosis or wall thickening of intra-renal arteries.</s><s>However, the massive increase in urinary MDA (Fig. <ref type="figure" target="#fig_0">1B</ref>) reflected the diabetes-related inflammatory rise of oxidative stress.</s><s>As already mentioned in the Study Design section, the lower susceptibility of C57BL/6J as compared to BLKS mice regarding DN may have contributed to the mildness of histological findings <ref type="bibr" target="#b24">[25,</ref><ref type="bibr" target="#b29">30]</ref>.</s><s>In retrospect, feeding a high-fat diet might have aggravated our model which was reported particularly for eNOS-KO mice <ref type="bibr" target="#b37">[38]</ref>.</s></p><p><s>At first sight, the ineffectiveness of Rlx to ameliorate DN in this study may appear contradictory to the many positive experimental studies mentioned above.</s><s>In more detail, Rlx was effective as anti-fibrotic agent in rodent models of renal papillary necrosis <ref type="bibr" target="#b38">[39]</ref>, glomerulonephritis <ref type="bibr" target="#b39">[40]</ref>, sub-total nephrectomy <ref type="bibr" target="#b40">[41]</ref>, spontaneous hypertension <ref type="bibr" target="#b11">[12]</ref>, and</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>This work aimed at investigating the effect of two different doses of continuously infused sc.</s><s>Rlx on the development and progression of DN and DC.</s><s>Our hypothesis of Rlx being a candidate remedy for this diabetesinduced organ damage was based on a large body of experimental evidence indicating remarkably potent anti-fibrotic, reno-protective and reno-vasodilating, endotheliumprotecting, anti-inflammatory, as well as endothelin-1-suppressing effects of the peptide <ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref>.</s></p><p><s>The main findings are as follows: 1) In a mouse model of type-1 diabetes characterized by early and moderate DN (glomerulosclerosis and albuminuria) and high overall mortality, neither a low nor a high dose of Rlx administered for 12 weeks resulted in changes of the course of disease.</s><s>2) The fact that TGF-β, the major target of Rlx's action against fibrotic damage, was obviously not involved in the pathology of our model may lend an explanation to the ineffectiveness of the peptide.</s><s>3) In our model, myocardial fibrosis, a hallmark of DC, was not induced so that the above-mentioned working hypothesis for DC could not be tested within the design of this study.</s><s>unilateral ureteric obstruction <ref type="bibr" target="#b10">[11]</ref>.</s><s>At closer look, however, those were models of severe interstitial fibrosis with concomitant glomerular sclerosis, and TGF-β was the major inducer of pathology.</s><s>In our type-1 diabetic model, TGF-β was obviously not activated, nor was its key down-stream transcription factor, phosphor-Smad-2/3 (Fig. <ref type="figure" target="#fig_2">3</ref>).</s><s>This may explain the missing efficacy of Rlx on this disease phenotype since the interference with TGF-β signaling poses the established pathway of Rlx's renal anti-fibrosis <ref type="bibr" target="#b41">[42,</ref><ref type="bibr" target="#b42">43]</ref>.</s><s>Keeping this in mind, our results do corroborate the study conducted by Wong et al. in mRen2/STZ rats <ref type="bibr" target="#b23">[24]</ref> in which Rlx similarly failed to affect a type-1 diabetes-related renal pathology with prevailing glomerulosclerosis and albuminuria, little if any interstitial fibrosis, and preserved glomerular filtration rate.</s></p><p><s>Notwithstanding these considerations, the question arises as to why TGF-β was not upregulated in this model as well as in the mRen2 rat.</s><s>First, overt TGF activation promoting tubulo-interstitial fibrosis -that can be detected in a whole-kidney Western blot -was usually found very late in comparable mice models of DN: A modest up-regulation of interstitial collagen III was reported at week 20 after STZ earliest <ref type="bibr" target="#b25">[26,</ref><ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b43">44]</ref>.</s><s>We had to stop our study prematurely because of the high mortality and sacrifice our animals at week 16 after STZ according to German animal welfare regulations.</s><s>Thus, it might well have been too early to detect and treat this later stage of DN which presumably involves TGF.</s><s>On the other hand, TGF-β is also a pivotal mediator of the early occurring diabetic glomerulosclerosis since it is usually up-regulated early in mesangial cells and podocytes <ref type="bibr" target="#b44">[45]</ref>.</s><s>It was not evaluated in the studies that established the eNOS-KO/STZ model <ref type="bibr" target="#b25">[26,</ref><ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b28">29]</ref> whether glomerular TGF was activated, but if we assume so, why then could Rlx have been ineffective?</s><s>Besides the absence of overt TGF-β activation in their rat model, Wong and coworkers <ref type="bibr" target="#b23">[24]</ref> also reported on the lack of RXFP1 protein expression in mesangial cells.</s><s>As these cells are the main players in early glomerulosclerosis <ref type="bibr" target="#b44">[45]</ref> this would lend another explanation for the ineffectiveness of Rlx.</s><s>The ultimate question, however, if there is RXFP1 protein expression in mouse mesangial cells cannot be answered conclusively at present: It is much more difficult to isolate primary mouse glomerular cells and, more importantly, there is no reliable antibody against mouse RXFP1 to date that could be used for immunohistochemistry. Accordingly, we are not aware of any findings elucidating this issue.</s><s>Instead of being activated, TGF-β was even slightly, but significantly down-regulated in the diabetic control group.</s><s>This can be a chance finding in a small group.</s><s>On the other hand, our type-1 diabetic model is associated with severe illness and cachexia (cp.</s><s>bodyweight in Table <ref type="table" target="#tab_0">1</ref>), and this may have impacted on the activation of latent TGF-β.</s><s>We hypothesize as follows: Plasmin and thrombospondin are the main TGF activators <ref type="bibr" target="#b45">[46]</ref>.</s><s>The activation of plasmin, in turn, is decreased in cachexia states owing to the up-regulation of plasminogen activator inhibitor <ref type="bibr" target="#b46">[47]</ref>.</s><s>Thrombospondin is mainly synthesized in adipose tissue <ref type="bibr" target="#b47">[48]</ref> which is progressively lost in cachexia although, admittedly, there is also thrombospondin expression in the kidneys <ref type="bibr" target="#b28">[29]</ref>.</s></p><p><s>In many models of renal pathology, oxidative stress and TGF-β activation are intricately linked and act synergistically <ref type="bibr" target="#b48">[49]</ref>.</s><s>In our model, oxidative stress, as measured by urinary MDA, and TGF regulation were dissociated.</s><s>It is, however, well conceivable that increased oxidative stress acted independently here, e. g., by inactivating neuronal NOS-derived NO which plays an established role in this particular model <ref type="bibr" target="#b25">[26]</ref>.</s><s>Alternatively, oxidative stress is known to activate the JNK pathway, a major player in renal disease, via thioredoxin oxidation <ref type="bibr" target="#b49">[50,</ref><ref type="bibr" target="#b50">51]</ref>.</s><s>With regard to the eNOS-knockout model chosen, we would like to emphasize that first, the NO-generating renal effect of Rlx is mediated via neuronal NOS <ref type="bibr" target="#b42">[43]</ref>, and second, that a pathological decline of eNOS function is also a fundamental contributor to human DN <ref type="bibr" target="#b51">[52,</ref><ref type="bibr" target="#b52">53]</ref>.</s><s>In other words, our model does not a priori preclude or limit the efficacy of the candidate drug.</s></p><p><s>Biological inactivity can be largely excluded as a potential cause for the inefficacy of Rlx in our model.</s><s>First, the pK i and pEC 50 values obtained with our synthetic and with recombinant Rlx in HEK-293T cells were identical and correspond well with data reported in the literature <ref type="bibr" target="#b53">[54]</ref><ref type="bibr" target="#b54">[55]</ref><ref type="bibr" target="#b55">[56]</ref><ref type="bibr" target="#b56">[57]</ref><ref type="bibr" target="#b57">[58]</ref><ref type="bibr" target="#b58">[59]</ref>.</s><s>Second, we determined final plasma values within the targeted range.</s><s>For comparison, Samuel et al. <ref type="bibr" target="#b31">[32]</ref> reported plasma levels between 20-40 ng/ml in mice at day 14 using a moderately higher dose of Rlx, 500 instead of 320 µg/kg/d.</s><s>The levels reported by Samuel and the level in the high-dose group measured here, ~6 ng/ml, are around the circulating level at maximum renal vasodilator response, ~11 ng/ml, as determined by Danielson and coworkers in conscious rats <ref type="bibr" target="#b30">[31]</ref>.</s></p><p><s>One may wonder why the Rlx-induced small, but significant inhibition of Smad activation was not followed by a therapeutic benefit.</s><s>We strongly believe that this is attributable to the fact that this signaling path was not up-regulated at all in the diabetic controls, which is in striking contrast to all cases in which Rlx was beneficial by mitigating an increased Smad phosphorylation <ref type="bibr" target="#b42">[43]</ref>.</s></p><p><s>We were not able to verify our hypothesis regarding DC in our model because no myocardial fibrosis developed.</s><s>The decrease in myocyte diameter was certainly related to the cachexia of the diabetic animals.</s><s>Admittedly, the absence of fibrosis cannot exclude DC which is characterized by generalized systolic and diastolic dysfunction as well as metabolic disturbances in the STZ model <ref type="bibr" target="#b27">[28]</ref>.</s><s>However, more detailed investigations including echocardiography and/or cardiac catheterization were not planned for this study owing to logistical considerations and animal welfare regulations.</s><s>In the type-1 diabetic mRen2/ STZ rat model, Samuel et al. reported beneficial effects of Rlx on myocardial fibrosis and the related diastolic dysfunction <ref type="bibr" target="#b22">[23]</ref>.</s><s>As discussed above, Rlx was not beneficial regarding the renal pathology of the very same model <ref type="bibr" target="#b23">[24]</ref>.</s><s>These facts may indicate 1) model-related differences in the development of DC (eNOS-KO/STZ mouse vs mRen2/STZ rat) and 2) organ-related differences (kidney vs heart) regarding the Rlx-susceptibility of the pathways involved.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion</head><p><s>We investigated a model showing early DN without overt tubulo-interstitial fibrosis and activation of the TGF-β-Smad-2/3 pathway.</s><s>In such a model, therapeutic doses of Rlx proved ineffective on readouts of disease severity.</s><s>However, the same may not apply to other models and types of diabetes.</s><s>Instead, Rlx should be tested in type-2 diabetes and the related endorgan damage.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1 .</head><label>1</label><figDesc><div><p><s>Fig. 1. (A) Albuminuria at baseline and at final examination.</s><s>Data are given as mean ± SEM. *, P &lt; 0.05 vs baseline; **, P &lt; 0.01 vs baseline; ##, P &lt; 0.01 vs non-diabetic control.</s><s>(B) Urinary levels of malonyldialdehyde (MDA) (in µmol/l) normalized to urinary creatinine levels (in mmol/l).</s><s>Data are given as mean ± SEM. **, P &lt; 0.01 vs baseline; ##, P &lt; 0.01 vs non-diabetic control.</s></p></div></figDesc><graphic coords="5,263.69,183.75,290.46,419.55" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2 .</head><label>2</label><figDesc><div><p><s>Fig. 2. Representative examples of histopathological findings.</s><s>(A) Non-diabetic control.</s><s>(B) Diabetic control.</s><s>(C) Diabetic low-dose Rlx.</s><s>(D) Diabetic high-dose Rlx.</s><s>Black asterisk indicates accumulation of PAS-positive glomerular matrix proteins, gray arrow indicates hypercellular mesangial enlargement, black arrow shows adhesion with outer membrane of Bowman capsula, and black triangle points to tubular atrophy.</s></p></div></figDesc><graphic coords="6,186.17,202.23,315.06,446.36" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 3 .</head><label>3</label><figDesc><div><p><s>Fig. 3. (A) TGF-β levels and phospho-Smad-2/3 levels (normalized to total Smad-2/3) in homogenates of renal tissue as determined by Western blotting.</s><s>Data are mean ± SEM, given in % of non-diabetic control values.</s><s>#, P &lt; 0.05 vs non-diabetic control; ##, P &lt; 0.01 vs non-diabetic control.</s><s>Numbers of experiments: control, 13; diabetic control, 12; diabetic low Rlx, 9; and diabetic high Rlx, 10. (B) Representative examples of Western blots for TGF-β and Smad-2/3.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Body weight and blood glucose (data are mean ± SEM).</s><s>*, P &lt; 0.05 vs baseline; **, P &lt; 0.01 vs baseline.</s><s>##, P &lt; 0.01 vs non-diabetic controls</s></p></div></figDesc><table /></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">DOI: 10.1159/000368484 Published online: March 05, 2015 © 2015 S. Karger AG, Basel www.karger.com/kbr</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">© 2015 S. Karger AG, Basel www.karger.com/kbr</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Published online: March 05, 2015 © 2015 S. Karger AG, Basel www.karger.com/kbr</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>This work was supported by a grant from the German Ministry for Education and Research (AiF KF2181502FR9) given to TBD and</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Disclosure Statement</head><p><s>PHARIS Biotec (W.</s><s>G. F.) manufactures and distributes shRlx-2 for laboratory use.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Abbreviations</head><p><s>DN, diabetic nephropathy; DC, diabetic cardiomyopathy; RAAS, renin-angiotensinaldosterone system; Rlx, human relaxin-2; STZ, streptozotocin; MDA, malonyldialdehyde; PAS, periodic acid-Schiff; ELISA, enzyme-linked immuno-sorbent assay.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Diabetic nephropathy in 2010: Alleviating the burden of diabetic nephropathy</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Gray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Cooper</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Nephrol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="71" to="73" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">The global burden of diabetes and its complications: an emerging pandemic</title>
		<author>
			<persName><surname>Van Ds</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Beulens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">T</forename><surname>Van Der Schouw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Grobbee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Neal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cardiovasc Prev Rehabil</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="S3" to="S8" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Diabetic cardiomyopathy: mechanisms, diagnosis and treatment</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Hayat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Khattar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Malik</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Sci (Lond)</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="page" from="539" to="557" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">New type of cardiomyopathy associated with diabetic glomerulosclerosis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Rubler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dlugash</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">Z</forename><surname>Yuceoglu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kumral</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Branwood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Grishman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Cardiol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="595" to="602" />
			<date type="published" when="1972">1972</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Mann</surname></persName>
		</author>
		<author>
			<persName><surname>Re</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mcqueen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Dyal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Schumacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pogue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Maggioni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Budaj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chaithiraphan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dickstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Keltai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Metsarinne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Oto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Parkhomenko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename><surname>Piegas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Svendsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Teo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yusuf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">372</biblScope>
			<biblScope unit="page" from="547" to="553" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Telmisartan, ramipril, or both in patients at high risk for vascular events</title>
		<author>
			<persName><forename type="first">S</forename><surname>Yusuf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Teo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pogue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Dyal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Copland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Schumacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Dagenais</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Sleight</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Anderson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">358</biblScope>
			<biblScope unit="page" from="1547" to="1559" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Relaxin family peptides and their receptors</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Bathgate</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Halls</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">T</forename><surname>Van Der Westhuizen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">E</forename><surname>Callander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kocan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Summers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Physiol Rev</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="page" from="405" to="480" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Activation of orphan receptors by the hormone relaxin</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Nakabayashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nishi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kumagai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kudo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">D</forename><surname>Sherwood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Hsueh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">295</biblScope>
			<biblScope unit="page" from="671" to="674" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Identification of the pregnancy hormone relaxin as glucocorticoid receptor agonist</title>
		<author>
			<persName><forename type="first">T</forename><surname>Dschietzig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bartsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Stangl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Baumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Stangl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">FASEB J</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="1536" to="1538" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Inhibition of markers of hepatic stellate cell activation by the hormone relaxin</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Bennett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Kharbanda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Tuma</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem Pharmacol</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="867" to="874" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Antifibrotic properties of relaxin: in vivo mechanism of action in experimental renal tubulointerstitial fibrosis</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">D</forename><surname>Hewitson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">Y</forename><surname>Ho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Samuel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endocrinology</title>
		<imprint>
			<biblScope unit="volume">151</biblScope>
			<biblScope unit="page" from="4938" to="4948" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">D</forename><surname>Lekgabe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kiriazis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">L</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Bathgate</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">J</forename><surname>Du</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Samuel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hypertension</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="412" to="418" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Samuel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">N</forename><surname>Unemori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Mookerjee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Bathgate</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Layfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Tregear</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">J</forename><surname>Du</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endocrinology</title>
		<imprint>
			<biblScope unit="volume">145</biblScope>
			<biblScope unit="page" from="4125" to="4133" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Relaxin ameliorates hypertension and increases nitric oxide metabolite excretion in angiotensin II but not N(omega)-nitro-L-arginine methyl ester hypertensive rats</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Sasser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Molnar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Baylis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hypertension</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="197" to="204" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">N</forename><surname>Unemori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Pickford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Salles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Piercy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">H</forename><surname>Grove</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Erikson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Amento</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page" from="2739" to="2745" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Serelaxin Is a More Efficacious Antifibrotic Than Enalapril in an Experimental Model of Heart Disease</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Samuel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Bodaragama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Chew</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Widdop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Royce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">D</forename><surname>Hewitson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hypertension</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="315" to="322" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Relaxin activates the L-argininenitric oxide pathway in vascular smooth muscle cells in culture</title>
		<author>
			<persName><forename type="first">D</forename><surname>Bani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Failli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Bello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Thiemermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Bani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bigazzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Masini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hypertension</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="1240" to="1247" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Essential role for vascular gelatinase activity in relaxin-induced renal vasodilation, hyperfiltration, and reduced myogenic reactivity of small arteries</title>
		<author>
			<persName><forename type="first">A</forename><surname>Jeyabalan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Novak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Danielson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Kerchner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Opett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">P</forename><surname>Conrad</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circ Res</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="page" from="1249" to="1257" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Relaxin improves TNF-alpha-induced endothelial dysfunction: the role of glucocorticoid receptor and phosphatidylinositol 3-kinase signalling</title>
		<author>
			<persName><forename type="first">T</forename><surname>Dschietzig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Brecht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bartsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Baumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Stangl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Alexiou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cardiovasc Res</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page" from="97" to="107" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Relaxin inhibits early steps in vascular inflammation</title>
		<author>
			<persName><forename type="first">A</forename><surname>Brecht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bartsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Baumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Stangl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Dschietzig</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Regul Pept</title>
		<imprint>
			<biblScope unit="volume">166</biblScope>
			<biblScope unit="page" from="76" to="82" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-kappaB</title>
		<author>
			<persName><forename type="first">T</forename><surname>Dschietzig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bartsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Richter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Laule</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Baumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Stangl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circ Res</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page" from="32" to="40" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Acute treatment with relaxin protects the kidney against ischaemia/reperfusion injury</title>
		<author>
			<persName><forename type="first">M</forename><surname>Collino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rogazzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Benetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Rosa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Chiazza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Fantozzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Masini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cell Mol Med</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="1494" to="1505" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Relaxin ameliorates fibrosis in experimental diabetic cardiomyopathy</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Samuel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">D</forename><surname>Hewitson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Kelly</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endocrinology</title>
		<imprint>
			<biblScope unit="volume">149</biblScope>
			<biblScope unit="page" from="3286" to="3293" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">The anti-fibrotic hormone relaxin is not reno-protective, despite being active, in an experimental model of type 1 diabetes</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Samuel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Kelly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Becker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">D</forename><surname>Hewitson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Protein Pept Lett</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="1029" to="1038" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Mouse models of diabetic nephropathy</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Brosius</surname></persName>
		</author>
		<author>
			<persName><surname>Iii</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Alpers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Bottinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Breyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Coffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Gurley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kakoki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kretzler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Leiter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Levi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Mcindoe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Smithies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Susztak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Takahashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Takahashi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Soc Nephrol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="2503" to="2512" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Deficiency of endothelial nitric-oxide synthase confers susceptibility to diabetic nephropathy in nephropathy-resistant inbred mice</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Kanetsuna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Takahashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nagata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Gannon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Breyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Takahashi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">170</biblScope>
			<biblScope unit="page" from="1473" to="1484" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy</title>
		<author>
			<persName><forename type="first">T</forename><surname>Nakagawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Sato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Glushakova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Heinig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Clarke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Campbell-Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yuzawa</forename><surname>Atkinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Croker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Soc Nephrol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="539" to="550" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Rodent models of diabetic cardiomyopathy</title>
		<author>
			<persName><forename type="first">H</forename><surname>Bugger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">D</forename><surname>Abel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dis Model Mech</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="454" to="466" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Lowering blood pressure blocks mesangiolysis and mesangial nodules, but not tubulointerstitial injury, in diabetic eNOS knockout mice</title>
		<author>
			<persName><forename type="first">T</forename><surname>Kosugi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Heinig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Nakayama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Connor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yuzawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">W</forename><surname>Hauswirth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Grant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">P</forename><surname>Croker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Campbell-Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Atkinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Segal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Nakagawa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">174</biblScope>
			<biblScope unit="page" from="1221" to="1229" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Role of endothelial nitric oxide synthase in diabetic nephropathy: lessons from diabetic eNOS knockout mice</title>
		<author>
			<persName><forename type="first">T</forename><surname>Takahashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Harris</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Diabetes Res</title>
		<imprint>
			<biblScope unit="page">590541</biblScope>
			<date type="published" when="2014">2014. 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Time course and dose response of relaxin-mediated renal vasodilation, hyperfiltration, and changes in plasma osmolality in conscious rats</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Danielson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">P</forename><surname>Conrad</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Appl Physiol</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page" from="1509" to="1514" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Relaxin deficiency in mice is associated with an age-related progression of pulmonary fibrosis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Samuel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Bathgate</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Bond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Burton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Parry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Summers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Amento</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Tregear</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">FASEB J</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="121" to="123" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Renoprotective effects of combined endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Sharkovska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kalk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Von</forename><surname>Wk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Relle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Pfab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Alter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Fischer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hocher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Lab</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="507" to="515" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Lack of endothelial nitric oxide synthase promotes endothelin-induced hypertension: lessons from endothelin-1 transgenic/endothelial nitric oxide synthase knockout mice</title>
		<author>
			<persName><forename type="first">T</forename><surname>Quaschning</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Voss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Relle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kalk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Vignon-Zellweger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Pfab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Theilig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bachmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kraemer-Guth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wanner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Theuring</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Galle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hocher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Soc Nephrol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="730" to="740" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Analysis of cardiac and renal endothelin receptors by in situ hybridization in mice</title>
		<author>
			<persName><forename type="first">N</forename><surname>Vignon-Zellweger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rahnenfuhrer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Theuring</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hocher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Lab</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="939" to="949" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Site-specific conjugation of a lanthanide chelator and its effects on the chemical synthesis and receptor binding affinity of human relaxin-2 hormone</title>
		<author>
			<persName><forename type="first">F</forename><surname>Shabanpoor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Bathgate</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Belgi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">B</forename><surname>Nair</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Wade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Hossain</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem Biophys Res Commun</title>
		<imprint>
			<biblScope unit="volume">420</biblScope>
			<biblScope unit="page" from="253" to="256" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Identification of the N-linked glycosylation sites of the human relaxin receptor and effect of glycosylation on receptor function</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Scott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">N</forename><surname>Wilkinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ji</forename><forename type="middle">J</forename><surname>Tregear</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Bathgate</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochemistry</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="6953" to="6968" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Elevated tissue factor expression contributes to exacerbated diabetic nephropathy in mice lacking eNOS fed a high fat diet</title>
		<author>
			<persName><forename type="first">F</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Thai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Boysen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Turner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Wolberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Mackman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Maeda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Takahashi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thromb Haemost</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="2122" to="2132" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Relaxin decreases renal interstitial fibrosis and slows progression of renal disease</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Garber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Mirochnik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Brecklin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">N</forename><surname>Unemori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Slobodskoy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">H</forename><surname>Grove</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Arruda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Dunea</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Int</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="876" to="882" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Effects of relaxin on development of mesangial proliferative nephritis</title>
		<author>
			<persName><forename type="first">N</forename><surname>Ikegaya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Yoshida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kohsaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Suzuki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kobayashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Yamamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Fujigaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hishida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kumagai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann N Y Acad Sci</title>
		<imprint>
			<biblScope unit="volume">1160</biblScope>
			<biblScope unit="page" from="300" to="303" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Effect of relaxin in two models of renal mass reduction</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Garber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Mirochnik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Brecklin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Slobodskoy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Arruda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Dunea</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Nephrol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="8" to="12" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Heeg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Koziolek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Vasko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Schaefer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Muller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Strutz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Int</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="96" to="109" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2</title>
		<author>
			<persName><forename type="first">I</forename><surname>Mookerjee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">D</forename><surname>Hewitson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Halls</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Summers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Mathai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Bathgate</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Tregear</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Samuel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">FASEB J</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="1219" to="1229" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">Y</forename><surname>Chow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Nikolic-Paterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Atkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">H</forename><surname>Tesch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">streptozotocin-induced diabetic nephropathy: potential role in renal fibrosis</title>
				<imprint>
			<date type="published" when="2004">2004</date>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="2987" to="2996" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Transforming growth factor-beta and the progression of renal disease</title>
		<author>
			<persName><forename type="first">I</forename><surname>Loeffler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Wolf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nephrol Dial Transplant</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="37" to="45" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">TGF-beta: an important mediator of allergic disease and a molecule with dual activity in cancer development</title>
		<author>
			<persName><forename type="first">B</forename><surname>Tirado-Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Ortega</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Segura-Medina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Huerta-Yepez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol Res</title>
		<imprint>
			<biblScope unit="page">318481</biblScope>
			<date type="published" when="2014">2014. 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Lysiak-Szydlowska W: L-carnitine and cancer cachexia. II. Effects of lipid emulsion used in total parenteral nutrition on parameters of hemostasis and inflammatory state in L-carnitine deficiency in myocytes</title>
		<author>
			<persName><forename type="first">J</forename><surname>Szefel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Kruszewski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ciesielski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Szajewski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kawecki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Jankun</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncol Rep</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="324" to="329" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">The role of thrombospondin (TSP)-1 in obesity and diabetes</title>
		<author>
			<persName><forename type="first">P</forename><surname>Kong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cavalera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">G</forename><surname>Frangogiannis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adipocyte</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="81" to="84" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Obesity, oxidative stress, and fibrosis in chronic kidney disease</title>
		<author>
			<persName><forename type="first">K</forename><surname>Sharma</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Int Suppl</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="113" to="117" />
			<date type="published" when="2011">2011. 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">The chemistry of cell signaling by reactive oxygen and nitrogen species and 4-hydroxynonenal</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Forman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Fukuto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rinna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Levy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Biochem Biophys</title>
		<imprint>
			<biblScope unit="volume">477</biblScope>
			<biblScope unit="page" from="183" to="195" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Recent insights into diabetic renal injury from the db/db mouse model of type 2 diabetic nephropathy</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">H</forename><surname>Tesch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Lim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Physiol Renal Physiol</title>
		<imprint>
			<biblScope unit="volume">300</biblScope>
			<biblScope unit="page" from="F301" to="F310" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Association of eNOS Glu298Asp polymorphism with end-stage renal disease</title>
		<author>
			<persName><forename type="first">E</forename><surname>Noiri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Satoh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Taguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">V</forename><surname>Brodsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nakao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ogawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nishijima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Yokomizo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Tokunaga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Fujita</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hypertension</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="535" to="540" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Role of nitric oxide in diabetic nephropathy</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Prabhakar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Nephrol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="333" to="344" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Relaxin-3: improved synthesis strategy and demonstration of its high-affinity interaction with the relaxin receptor LGR7 both in vitro and in vivo</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Bathgate</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">F</forename><surname>Hanson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Otvos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jr</forename><surname>Guidolin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Giannakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bastiras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Layfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Ferraro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gundlach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Samuel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Tregear</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Wade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochemistry</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="1043" to="1053" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Identification of key residues essential for the structural fold and receptor selectivity within the A-chain of human gene-2 (H2) relaxin</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Rosengren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Layfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Bathgate</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Separovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Samuel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Hossain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Wade</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">287</biblScope>
			<biblScope unit="page" from="41152" to="41164" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Relaxin activates multiple cAMP signaling pathway profiles in different target cells</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Halls</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">D</forename><surname>Hewitson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">L</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">J</forename><surname>Du</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Bathgate</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Summers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann NY Acad Sci</title>
		<imprint>
			<biblScope unit="volume">1160</biblScope>
			<biblScope unit="page" from="108" to="111" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">The A-chain of human relaxin family peptides has distinct roles in the binding and activation of the different relaxin family peptide receptors</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Hossain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Rosengren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Haugaard-Jonsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Layfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ferraro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">L</forename><surname>Daly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Tregear</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Wade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Bathgate</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">283</biblScope>
			<biblScope unit="page" from="17287" to="17297" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">The minimal active structure of human relaxin-2</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Hossain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Rosengren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Samuel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Shabanpoor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Bathgate</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Wade</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">286</biblScope>
			<biblScope unit="page" from="37555" to="37565" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">The different ligand-binding modes of relaxin family peptide receptors RXFP1 and RXFP2</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Scott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Rosengren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Bathgate</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Endocrinol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="1896" to="1906" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
